The Value of Optical Coherence Tomography in Patients with Pituitary Adenoma and Its Association with Clinical Features: A Pilot Study.
Saved in:
| Title: | The Value of Optical Coherence Tomography in Patients with Pituitary Adenoma and Its Association with Clinical Features: A Pilot Study. |
|---|---|
| Authors: | Duseikaite M; Laboratory of Ophthalmology, Institute of Neuroscience, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50161 Kaunas, Lithuania., Vilkeviciute A; Laboratory of Ophthalmology, Institute of Neuroscience, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50161 Kaunas, Lithuania., Dumbliauskaite I; Medical Academy, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50161 Kaunas, Lithuania., Glebauskiene B; Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50161 Kaunas, Lithuania., Zostautiene I; Radiology Department, Medicine Academy, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50161 Kaunas, Lithuania., Rovite V; Latvian Biomedical Research and Study Centre, Ratsupites Str. 1-k1, LV-1067 Riga, Latvia., Wu SN; Department of Neurology, National Cheng Kung University Hospital, Tainan City 704, Taiwan., Tamasauskas A; Department of Neurosurgery, Hospital of Lithuanian University of Health Sciences, Kaunas Clinics, LT-50161 Kaunas, Lithuania., Liutkeviciene R; Laboratory of Ophthalmology, Institute of Neuroscience, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50161 Kaunas, Lithuania. |
| Source: | Journal of clinical medicine [J Clin Med] 2025 Jun 17; Vol. 14 (12). Date of Electronic Publication: 2025 Jun 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
